Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: Efficacy and toxicity in breast cancer xenografts

Synergistic multimodality therapy is needed for breast cancer. Breast cancer frequently has p53 mutations that result in cells less likely to undergo apoptosis when exposed to DNA damaging therapies. Taxol (paclitaxel) is more effective in the presence of mutant p53. (90)Y-labeled DOTA-peptide-ChL6...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Proc Natl Acad Sci U S A
Principais autores:	DeNardo, Sally J., Kukis, David L., Kroger, Linda A., O’Donnell, Robert T., Lamborn, Kathleen R., Miers, Laird A., DeNardo, David G., Meares, Claude F., DeNardo, Gerald L.
Formato:	Artigo
Idioma:	Inglês
Publicado em:	National Academy of Sciences 1997
Assuntos:	Biological Sciences
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC20557/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9108094/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.94.8.4000
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!